Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine?-Reference-Cited by-同舟云学术

Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine?

Published:2020-07-11 Issue:3 Volume:70 Page:552-557
ISSN:1355-008X
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Rosario Pedro Weslley^ORCID,Mourão Gabriela Franco,Calsolari Maria Regina

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s12020-020-02414-1.pdf

Reference37 articles.

1. G.W. Randolph, Q.Y. Duh, K.S. Heller, V.A. LiVolsi, S.J. Mandel, D.L. Steward, R.P. Tufano, R.M. Tuttle, American Thyroid Association Surgical Affairs Committee’s Taskforce on Thyroid Cancer Nodal Surgery. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22, 1144–1152 (2012)

2. B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)

3. A.L. Mitchell, A. Gandhi, D. Scott-Coombes, P. Perros, Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J. Laryngol. Otol. 130, S150–S160 (2016)

4. S. Zerdoud, A.L. Giraudet, S. Leboulleux, L. Leenhardt, S. Bardet, J. Clerc, M.E. Toubert, A. Al Ghuzlan, P.J. Lamy, C. Bournaud, I. Keller, F. Sebag, R. Garrel, E. Mirallié, L. Groussin, E. Hindié, D. Taïeb, Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. Ann. Endocrinol. 78, 162–175 (2017)

5. F. Pacini, F. Basolo, R. Bellantone, G. Boni, M.A. Cannizzaro, M. De Palma, C. Durante, R. Elisei, G. Fadda, A. Frasoldati, L. Fugazzola, R. Guglielmi, C.P. Lombardi, P. Miccoli, E. Papini, G. Pellegriti, L. Pezzullo, A. Pontecorvi, M. Salvatori, E. Seregni, P. Vitti, Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. J. Endocrinol. Investig. 41, 849–876 (2018)

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term efficacy of lobectomy for stage T1 papillary thyroid carcinoma with varying degrees of lymph node metastasis;Frontiers in Endocrinology;2024-08-08

2. Comment on: Lymph node ratio independently associated with postoperative thyroglobulin levels in papillary thyroid cancer;Oral Oncology;2024-05

3. m6A mRNA methylation initiated by METTL3 inhibits KDR translation to increase the efficacy of 131I therapy in papillary thyroid carcinoma;Journal of Radioanalytical and Nuclear Chemistry;2023-05-25

4. Response to Surgery Assessments for Sparing Radioiodine Remnant Ablation in Intermediate-Risk Papillary Thyroid Cancer;The Journal of Clinical Endocrinology & Metabolism;2022-12-26

5. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies;Clinical Endocrinology;2021-08-04